$SLRX
Salarius Pharmaceuticals, Inc.

2021 Q4 Form 10-Q Financial Statement

#000161521921000093 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $1.378M
YoY Change -100.0% -100.0% 57.52%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.449M $1.731M $1.330M
YoY Change 19.77% 30.13% -61.89%
% of Gross Profit
Research & Development $2.696M $2.016M $1.804M
YoY Change 33.45% 11.77% 58.09%
% of Gross Profit
Depreciation & Amortization $4.790K $4.800K $0.00
YoY Change -52.1%
% of Gross Profit
Operating Expenses $4.145M $3.747M $3.137M
YoY Change 27.93% 19.44% -32.33%
Operating Profit -$3.747M -$1.759M
YoY Change 113.06% -53.23%
Interest Expense $39.99K $487.00 -$3.230K
YoY Change -499.9% -115.08% 329.52%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change
Pretax Income -$4.105M -$3.737M -$1.720M
YoY Change 131.91% 117.27% -34.6%
Income Tax
% Of Pretax Income
Net Earnings -$4.105M -$3.737M -$1.717M
YoY Change 131.91% 117.7% -34.67%
Net Earnings / Revenue -124.55%
Basic Earnings Per Share -$0.08 -$0.10
Diluted Earnings Per Share -$90.67K -$0.08 -$0.10
COMMON SHARES
Basic Shares Outstanding 45.21M shares 44.80M shares 17.97M shares
Diluted Shares Outstanding 44.80M shares 17.97M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.21M $31.90M $9.600M
YoY Change 163.19% 232.33% 140.0%
Cash & Equivalents $29.21M $31.90M $9.558M
Short-Term Investments
Other Short-Term Assets $173.0K $95.23K $139.9K
YoY Change 25.55% -31.94% 17.6%
Inventory
Prepaid Expenses
Receivables $0.00 $2.086M $3.200M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $30.16M $35.18M $13.92M
YoY Change 90.95% 152.77% 165.66%
LONG-TERM ASSETS
Property, Plant & Equipment $7.880K $11.57K $15.64K
YoY Change -65.19% -26.0% -44.45%
Goodwill $8.866M $8.866M $8.866M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $193.9K $201.4K $262.5K
YoY Change -21.54% -23.28% -19.11%
Total Long-Term Assets $10.67M $9.079M $9.144M
YoY Change 16.8% -0.71% -0.81%
TOTAL ASSETS
Total Short-Term Assets $30.16M $35.18M $13.92M
Total Long-Term Assets $10.67M $9.079M $9.144M
Total Assets $40.83M $44.26M $23.06M
YoY Change 63.78% 91.92% 59.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.543M $1.235M $1.195M
YoY Change -16.76% 3.34% -27.27%
Accrued Expenses $553.3K $323.4K $400.0K
YoY Change 38.32% -19.16% 100.0%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00 $800.0K
YoY Change -100.0% -100.0% 14.29%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.111M $1.612M $2.500M
YoY Change -24.61% -35.51% -46.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.111M $1.612M $2.500M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.111M $1.612M $2.457M
YoY Change -23.88% -34.39% -47.95%
SHAREHOLDERS EQUITY
Retained Earnings -$32.20M -$28.09M -$17.66M
YoY Change 65.72% 59.06% 73.26%
Common Stock $4.524K $4.517K $1.981K
YoY Change 90.0% 128.02% -47.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.72M $42.65M $20.61M
YoY Change
Total Liabilities & Shareholders Equity $40.83M $44.26M $23.06M
YoY Change 63.78% 91.92% 59.52%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$4.105M -$3.737M -$1.717M
YoY Change 131.91% 117.7% -34.67%
Depreciation, Depletion And Amortization $4.790K $4.800K $0.00
YoY Change -52.1%
Cash From Operating Activities -$2.721M -$1.582M -$2.760M
YoY Change 98.58% -42.68% -50.18%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 31.25K 406.4K 5.090M
YoY Change -98.93% -92.02% -2523.81%
NET CHANGE
Cash From Operating Activities -2.721M -1.582M -2.760M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 31.25K 406.4K 5.090M
Net Change In Cash -2.689M -1.176M 2.330M
YoY Change -272.39% -150.46% -1764.29%
FREE CASH FLOW
Cash From Operating Activities -$2.721M -$1.582M -$2.760M
Capital Expenditures $0.00
Free Cash Flow -$2.721M
YoY Change 98.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001615219
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#GrantMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#GrantMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#GrantMember
CY2020Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#GrantMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36812
dei Entity Registrant Name
EntityRegistrantName
SALARIUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5087339
dei Entity Address Address Line1
EntityAddressAddressLine1
2450 Holcombe Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite X
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77021
dei City Area Code
CityAreaCode
832
dei Local Phone Number
LocalPhoneNumber
834-6992
dei Security12b Title
Security12bTitle
Common Stock, $ 0.0001 par value
dei Trading Symbol
TradingSymbol
SLRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45206135 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31903727 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11118614 USD
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
2086157 USD
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
3855996 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1194255 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
822050 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
35184139 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
15796660 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11570 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22639 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
201389 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
247113 USD
CY2021Q3 us-gaap Goodwill
Goodwill
8865909 USD
CY2020Q4 us-gaap Goodwill
Goodwill
8865909 USD
CY2021Q3 us-gaap Assets
Assets
44263007 USD
CY2020Q4 us-gaap Assets
Assets
24932321 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1234922 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1853756 USD
CY2021Q3 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
323364 USD
CY2020Q4 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
383138 USD
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
477028 USD
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
54006 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
59211 USD
CY2021Q3 us-gaap Liabilities
Liabilities
1612292 USD
CY2020Q4 us-gaap Liabilities
Liabilities
2773133 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45172535 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23810541 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45172535 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23808546 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
4517 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2381 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
70738517 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
41585761 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28092319 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19428954 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
42650715 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22159188 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44263007 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24932321 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1378239 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1840216 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3754379 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2015930 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1803682 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5852887 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4890375 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1730730 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1333062 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4655404 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4893021 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
3746660 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
3136744 USD
us-gaap Operating Expenses
OperatingExpenses
10508291 USD
us-gaap Operating Expenses
OperatingExpenses
9783396 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3746660 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1758505 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8668075 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6029017 USD
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9073 USD
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-45103 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5205 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-265538 USD
CY2021Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 USD
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
179027 USD
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
487 USD
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3230 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-495 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-254 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3737100 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1716632 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-8663365 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5584706 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3737100 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1716632 USD
us-gaap Net Income Loss
NetIncomeLoss
-8663365 USD
us-gaap Net Income Loss
NetIncomeLoss
-5584706 USD
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44804741 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44804741 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17968664 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17968664 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40064119 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40064119 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13833410 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13833410 shares
us-gaap Net Income Loss
NetIncomeLoss
-8663365 USD
us-gaap Net Income Loss
NetIncomeLoss
-5584706 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14387 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12699 USD
us-gaap Share Based Compensation
ShareBasedCompensation
413153 USD
us-gaap Share Based Compensation
ShareBasedCompensation
149660 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
25000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5205 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-265538 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1769839 USD
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3212678 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
329799 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-799210 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-618830 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-607904 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-59774 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
288079 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-541701 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7479594 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8937879 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
27256384 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
14810945 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1485351 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
636214 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
477028 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
690367 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28264707 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14756792 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20785113 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5818913 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11118614 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3738900 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31903727 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9557813 USD
us-gaap Interest Paid Net
InterestPaidNet
1468 USD
us-gaap Interest Paid Net
InterestPaidNet
6615 USD
flks Stock Issuance Costs Accrued And Amortized
StockIssuanceCostsAccruedAndAmortized
0 USD
flks Stock Issuance Costs Accrued And Amortized
StockIssuanceCostsAccruedAndAmortized
12001 USD
flks Prepaid Expense Financed By Note Payable
PrepaidExpenseFinancedByNotePayable
USD
flks Prepaid Expense Financed By Note Payable
PrepaidExpenseFinancedByNotePayable
949131 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
10580854 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9467166 USD
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
38409 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2083816 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
18002613 USD
CY2020Q2 flks Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
578714 USD
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
32905 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1784258 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
16854974 USD
CY2020Q3 flks Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
57500 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5331778 USD
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
78346 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1716632 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
20605966 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22159188 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26850021 USD
CY2021Q1 flks Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1485351 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
135379 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1851896 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
48778043 USD
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
147456 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3074369 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
45851130 USD
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
130322 USD
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
406363 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3737100 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
42650715 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div>
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2021Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (“FDIC”). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9531198 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10075278 shares
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
95231 USD
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
2100000 USD
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
3900000 USD
CY2021Q3 flks Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
135227 USD
CY2020Q4 flks Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
0 USD
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
963797 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
684268 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
137782 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1194255 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
822050 USD
CY2016Q2 flks Revenue From Grants Maximum Award
RevenueFromGrantsMaximumAward
18700000 USD
CY2016Q3 flks Revenue From Grants Maximum Award
RevenueFromGrantsMaximumAward
16100000 USD
CY2016Q2 flks Revenue From Grants Award Term
RevenueFromGrantsAwardTerm
P3Y
CY2021Q3 flks Revenue From Grants Revenue Sharing Payments Continued Payments Percent Of Net Sales
RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales
0.01
CY2021Q3 flks Revenue From Grants Matching Funds Requirement
RevenueFromGrantsMatchingFundsRequirement
0.50
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
2100000 USD
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
3900000 USD
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3964065 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3964065 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3964065 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.182
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6200000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23000000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1500000 USD
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
142711 shares
CY2021Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.17
CY2019Q3 flks Class Of Warrant Or Right Threshold Consecutive Trading Days
ClassOfWarrantOrRightThresholdConsecutiveTradingDays
10 day
CY2021Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y3M21D
CY2020Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P4Y21D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
79000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
100000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
700000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0100
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0109
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0093
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3335
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3106
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3044
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
166233 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.42
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M10D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
743118 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.61
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
36613 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
30766 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
841972 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M25D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
69813 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
37.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y5M4D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1563972 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.78
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y5M19D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
175770 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
79000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
45000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1597972 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
271540 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
323730 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.27
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M26D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
34440 USD
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1000000.0 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
400000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M12D

Files In Submission

Name View Source Status
0001615219-21-000093-index-headers.html Edgar Link pending
0001615219-21-000093-index.html Edgar Link pending
0001615219-21-000093.txt Edgar Link pending
0001615219-21-000093-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
flks-20210930.htm Edgar Link pending
flks-20210930.xsd Edgar Link pending
flks-20210930_cal.xml Edgar Link unprocessable
flks-20210930_def.xml Edgar Link unprocessable
flks-20210930_htm.xml Edgar Link completed
flks-20210930_lab.xml Edgar Link unprocessable
flks-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slrx20210930ex-311.htm Edgar Link pending
slrx20210930ex-312.htm Edgar Link pending
slrx20210930ex-321.htm Edgar Link pending